Table 4. Changes in T cell activation and soluble markers aggregating the 12 weeks on mesalamine.
| Mesalamine (n = 27) | |||
| Biomarker | Baseline Median (%) | Mean Δ in log10% (95% CI) | P Value |
| CD38+HLA-DR+38+ CD8+ T Cells | 13.9 | 0.0003 (−0.09 to 0.09) | 0.99 |
| CD38+HLA-DR+38+ CD4+ T Cells | 4.4 | 0.01 (−0.06 to 0.09) | 0.73 |
| IL-17+CD4+ T cells | 0.93 | −0.10 (−0.32 to 0.12) | 0.37 |
| FoxP3+CD25+ CD4+ T cells | 9.68 | 0.03 (−0.05 to 0.10) | 0.48 |
| CD4+ T cell (cells/mm3) | 246 | 0.001 (−0.03 to 0.04) | 0.95 |
| sCD14 (ng/ml) | 1,604 | 0.008 (−0.08 to 0.09) | 0.86 |
| IL-6 (pg/ml) | 1.46 | −0.05 (−0.16 to 0.06) | 0.37 |
| D-dimer (ng/ml) | 480 | −0.02 (−0.14 to 0.09) | 0.69 |
| K:T ratio | 41 | 0.008 (−0.02 to 0.04) | 0.59 |
| FMD (%) | 4.78 | 0.007 (−0.05 to 0.07) | 0.83 |
| Brachial artery diameter (mm) | 4.55 | −0.002 (−0.006 to 0.002) | 0.38 |
| Hyperemic velocity (cm) | 73.1 | −0.002 (−0.08 to 0.07) | 0.96 |
| Viral load (copy/ml) | 0.86 | −0.11 (−0.28 to 0.07) | 0.23 |